4-硝基-6-溴-1H-吲唑 | 885518-46-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 中文名称: 4-硝基-6-溴-1H-吲唑
• 中文别名: 6-溴-4-硝基吲唑
• 英文名称: 6-bromo-4-nitro-1H-indazole
• 英文别名: 4-nitro-6-bromo-1H-indazole
• CAS: 885518-46-7
• 化学式: C₇H₄BrN₃O₂
• 分子量: 242.032
• InChiKey: AHEMYGJJCOXPSP-UHFFFAOYSA-N

物化性质

• 沸点：
  420.8±25.0 °C(Predicted)
• 密度：
  1.965

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  74.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933990090
• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H317,H319
• 储存条件：
  室温且干燥环境下使用。

SDS

---

SECTION 1: Identification of the substance/mixture and of the company/undertaking
Product identifiers
Product name : 6-Bromo-4-Nitro-1H-Indazole
REACH No. : A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

SECTION 2: Hazards identification
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008
Acute toxicity, Oral (Category 3), H301
For the full text of the H-Statements mentioned in this Section, see Section 16.
Classification according to EU Directives 67/548/EEC or 1999/45/EC
T Toxic R25
For the full text of the R-phrases mentioned in this Section, see Section 16.
Label elements
Labelling according Regulation (EC) No 1272/2008
Pictogram
Signal word Danger
Hazard statement(s)
H301 Toxic if swallowed.
Precautionary statement(s)
P301 + P310 IF SWALLOWED: Immediately call a POISON CENTER or doctor/
physician.
Supplemental Hazard none
Statements
Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumulative and
toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

---

SECTION 3: Composition/information on ingredients
Substances
Molecular weight : 242,03 g/mol
Hazardous ingredients according to Regulation (EC) No 1272/2008
Component Classification Concentration
6-Bromo-4-Nitro-1H-Indazole
Acute Tox. 3; H301 <= 100 %
Hazardous ingredients according to Directive 1999/45/EC
Component Classification Concentration
6-Bromo-4-Nitro-1H-Indazole
T, R25 <= 100 %
For the full text of the H-Statements and R-Phrases mentioned in this Section, see Section 16

---

SECTION 4: First aid measures
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Take victim immediately to hospital. Consult a physician.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
section 11
Indication of any immediate medical attention and special treatment needed
No data available

---

SECTION 5: Firefighting measures
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Nature of decomposition products not known.
Advice for firefighters
Wear self-contained breathing apparatus for firefighting if necessary.
Further information
No data available

---

SECTION 6: Accidental release measures
Personal precautions, protective equipment and emergency procedures
Wear respiratory protection. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure
adequate ventilation. Evacuate personnel to safe areas. Avoid breathing dust.
For personal protection see section 8.
Environmental precautions
Prevent further leakage or spillage if safe to do so. Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

SECTION 7: Handling and storage
Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.
For precautions see section 2.2.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Storage class (TRGS 510): Non-combustible, acute toxic Cat.3 / toxic hazardous materials or hazardous
materials causing chronic effects
Specific end use(s)
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated

---

SECTION 8: Exposure controls/personal protection
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Avoid contact with skin, eyes and clothing. Wash hands before breaks and immediately after handling
the product.
Personal protective equipment
Eye/face protection
Face shield and safety glasses Use equipment for eye protection tested and approved under
appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Complete suit protecting against chemicals, The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Where risk assessment shows air-purifying respirators are appropriate use a full-face particle
respirator type N99 (US) or type P2 (EN 143) respirator cartridges as a backup to engineering
controls. If the respirator is the sole means of protection, use a full-face supplied air respirator. Use
respirators and components tested and approved under appropriate government standards such
as NIOSH (US) or CEN (EU).
Control of environmental exposure
Prevent further leakage or spillage if safe to do so. Do not let product enter drains.

---

SECTION 9: Physical and chemical properties
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour No data available
c) Odour Threshold No data available
d) pH No data available
e) Melting point/freezing No data available
point
f) Initial boiling point and No data available
boiling range
g) Flash point No data available
h) Evaporation rate No data available
i) Flammability (solid, gas) No data available
j) Upper/lower No data available
flammability or
explosive limits
k) Vapour pressure No data available
l) Vapour density No data available
m) Relative density No data available
n) Water solubility No data available
o) Partition coefficient: n- No data available
octanol/water
p) Auto-ignition No data available
temperature
q) Decomposition No data available
temperature
r) Viscosity No data available
s) Explosive properties No data available
t) Oxidizing properties No data available
Other safety information
No data available

---

SECTION 10: Stability and reactivity
Reactivity
No data available
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
No data available
Conditions to avoid
No data available
Incompatible materials
No data available
Hazardous decomposition products
In the event of fire: see section 5

---

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity
No data available
Skin corrosion/irritation
No data available
Serious eye damage/eye irritation
No data available
Respiratory or skin sensitisation
No data available
Germ cell mutagenicity
No data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
No data available
Specific target organ toxicity - single exposure
No data available
Specific target organ toxicity - repeated exposure
No data available
Aspiration hazard
No data available
Additional Information
RTECS: Not available

---

SECTION 12: Ecological information
Toxicity
No data available
Persistence and degradability
No data available
Bioaccumulative potential
No data available
Mobility in soil
No data available
Results of PBT and vPvB assessment
This substance/mixture contains no components considered to be either persistent, bioaccumulative and
toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.
Other adverse effects
No data available

---

SECTION 13: Disposal considerations
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Dissolve or mix the material
with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

---

SECTION 14: Transport information
UN number
ADR/RID: 2811 IMDG: 2811 IATA: 2811
UN proper shipping name
ADR/RID: TOXIC SOLID, ORGANIC, N.O.S. (6-Bromo-4-Nitro-1H-Indazole)
IMDG: TOXIC SOLID, ORGANIC, N.O.S. (6-Bromo-4-Nitro-1H-Indazole)
IATA: Toxic solid, organic, n.o.s. (6-Bromo-4-Nitro-1H-Indazole)
Transport hazard class(es)
ADR/RID: 6.1 IMDG: 6.1 IATA: 6.1
Packaging group
ADR/RID: III IMDG: III IATA: III
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
No data available

---

SECTION 15: Regulatory information
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
No data available
Chemical Safety Assessment
For this product a chemical safety assessment was not carried out

---

SECTION 16: Other information
Full text of H-Statements referred to under sections 2 and 3.
Acute Tox. Acute toxicity
H301 Toxic if swallowed.
Full text of R-phrases referred to under sections 2 and 3
T Toxic
R25 Toxic if swallowed.
Further information
Copyright 2014 Co. LLC. License granted to make unlimited paper copies for internal use
only.
The above information is believed to be correct but does not purport to be all inclusive and shall be
used only as a guide. The information in this document is based on the present state of our knowledge
and is applicable to the product with regard to appropriate safety precautions. It does not represent any
guarantee of the properties of the product. Corporation and its Affiliates shall not be held
liable for any damage resulting from handling or from contact with the above product. See
and/or the reverse side of invoice or packing slip for additional terms and conditions of sale.

反应信息

• 作为反应物：
  描述：

  4-硝基-6-溴-1H-吲唑 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 4-甲基苯磺酸吡啶 、 碳酸氢钠 作用下， 以 二氯甲烷 、 水 、 异丙醇 为溶剂， 反应 4.67h， 生成 6-(1H-indol-4-yl)-4-nitro-2-(tetrahydro-2H-pyran-2-yl)-2H-indazole
  参考文献：
  名称：

  [EN] NOVEL COMPOUNDS
  [FR] NOUVEAUX COMPOSÉS

  摘要：

  这项发明涉及某些新颖化合物。具体而言，该发明涉及式(I)的化合物及其盐。该发明的化合物是PI3-激酶活性的抑制剂。

  公开号：

  WO2009147189A1
• 作为产物：
  描述：

  2,6-二硝基甲苯 在 盐酸 、 1,3-二溴-5,5-二甲基海因 、 硫酸 、 铁粉 、 溶剂黄146 、 sodium nitrite 作用下， 以 1,4-二氧六环 、 甲醇 、 水 为溶剂， 反应 12.75h， 生成 4-硝基-6-溴-1H-吲唑
  参考文献：
  名称：

  4,6-Substituted-1H-Indazoles 作为有效的 IDO1/TDO 双重抑制剂。

  摘要：

  吲哚胺 2,3-双加氧酶 1 (IDO1) 和色氨酸 2,3-双加氧酶 (TDO) 在许多类型的癌细胞中组成型过度表达并发挥重要的免疫抑制功能。在本文中，合成了一系列 4,6-取代-1H-吲唑衍生物并评估了对 IDO1 和 TDO 的抑制活性，以及​​它们的构效关系 (SAR)。其中，化合物 35 显示出最强的 IDO1 抑制效力，在酶促测定中的 IC50 值为 0.74 μM，在 HeLa 细胞中的 IC50 值为 1.37 μM。蛋白质印迹结果的定量分析表明，35 以浓度依赖性方式显着降低 INFγ 诱导的 IDO1 表达。此外，35 显示出有希望的 TDO 抑制，在酶促测定中的 IC50 值为 2.93 μM，在 A172 细胞中为 7.54 μM。而且，化合物35在CT26异种移植模型中表现出体内抗肿瘤活性。这些发现表明 1H-吲唑衍生物 35 是一种有效的 IDO1/TDO 双重抑制剂，具有开发用于

  DOI：

  10.1016/j.bmc.2019.02.014

文献信息

• Discovery and preliminary structure–activity relationship of 1H-indazoles with promising indoleamine-2,3-dioxygenase 1 (IDO1) inhibition properties
  作者：Shan Qian、Tao He、Wei Wang、Yanying He、Man Zhang、Lingling Yang、Guobo Li、Zhouyu Wang

  DOI：10.1016/j.bmc.2016.10.003

  日期：2016.12

  necessary for IDO1 inhibition, and the substituent groups at the both 4-position and 6-position largely affect inhibitory activity. The docking model exhibited that the effective interactions of 1H-indazoles with ferrous ion of heme and key residues of hydrophobic Pocket A and B ensured the IDO1 inhibitory activities. The study suggested that the 1H-indazole was a novel interesting scaffold for IDO

  吲哚胺2,3-双加氧酶1（IDO1）介导的色氨酸降解的犬尿氨酸途径被确定为逃避潜在有效免疫应答的肿瘤细胞中重要的免疫效应子途径。IDO1是抗癌治疗的一个有吸引力的靶标，并且IDO1抑制剂的发现在学术研究实验室和制药组织中都在紧锣密鼓地进行中。我们的研究发现1H-吲唑是一种具有重要IDO1抑制活性的新型关键药效团。合成了一系列新的1H-吲唑衍生物并确定了酶抑制活性，化合物2g表现出最高的活性，IC50值为5.3μM。1H-吲唑衍生物作为新型IDO1抑制剂的结构活性关系（SARs）分析表明1H-吲唑支架对于IDO1抑制是必需的，并且4位和6位的取代基都对抑制活性有很大影响。 。对接模型显示1H-吲唑与血红素亚铁离子以及疏水性口袋A和B的关键残基的有效相互作用确保了IDO1抑制活性。研究表明1H-吲唑是抑制IDO进一步发展的一种新颖有趣的支架。对接模型显示1H-吲唑与血红素亚铁离子以及疏水性口袋
• [EN] BENZPYRAZOL DERIVATIVES AS INHIBITORS OF PI3 KINASES<br/>[FR] DÉRIVÉS DE BENZPYRAZOLE EN TANT QU'INHIBITEURS DE P13 KINASES
  申请人：GLAXO GROUP LTD

  公开号：WO2009147188A1

  公开（公告）日：2009-12-10

  The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I) and salts thereof. The compounds of the invention are inhibitors of PI3-kinase activity.

  这项发明涉及某些新颖化合物。具体来说，该发明涉及式(I)的化合物及其盐。该发明的化合物是PI3-激酶活性的抑制剂。
• 吲唑类化合物及其在制备IDO抑制剂类药物 上的用途
  申请人：西华大学

  公开号：CN108689937B

  公开（公告）日：2021-09-17

  本发明公开了一种式(Ⅰ)或式(Ⅱ)所示的吲唑类化合物，还公开了所述化合物的制备方法和作为IDO抑制剂的用途。本发明的化合物可以用于预防和/或治疗多种疾病，如阿尔茨海默病、白内障、细胞免疫激活相关的感染、自身免疫性疾病、艾滋病、癌症、抑郁症或色氨酸代谢异常等。
• [EN] BENZPYRAZOLE DERIVATIVES AS INHIBITORS OF P13 KINASES<br/>[FR] DÉRIVÉS DE BENZPYRAZOLE COMME INHIBITEURS DES PI3 KINASES
  申请人：GLAXO GROUP LTD

  公开号：WO2011067365A1

  公开（公告）日：2011-06-09

  The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I) and salts thereof. The compounds of the invention are inhibitors of PI3-kinase activity.

  这项发明涉及某些新颖化合物。具体来说，该发明涉及式(I)的化合物及其盐。该发明的化合物是PI3-激酶活性的抑制剂。
• [EN] INDAZOLE DERIVATIVES AS PI 3 - KINASE INHIBITORS<br/>[FR] DÉRIVÉS D'INDAZOLE COMME INHIBITEURS DES PI3-KINASES
  申请人：GLAXO GROUP LTD

  公开号：WO2011067366A1

  公开（公告）日：2011-06-09

  The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I) and salts thereof. The compounds of the invention are inhibitors of PI3-kinase activity.

  这项发明涉及某些新颖化合物。具体而言，该发明涉及具有化学式(I)及其盐的化合物。该发明的化合物是PI3-激酶活性的抑制剂。